CTRI/2020/06/026087已完成2 期
A phase II, randomized, controlled, open-label study toevaluate the efficacy and safety of Pegylated IFN alfa-2b inthe treatment of adult patients diagnosed with SARS-CoV2(COVID-19).
Cadila Healthcare Limited Zydus Research Center0 个研究点目标入组 40 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Ability to comprehend and willingness to sign a written ICF for the study.
- •2. Male or non-pregnant females, >=18 years of age at the time of enrolment.
- •3. Understands and agrees to comply with planned study procedures.
- •4. Agrees to the collection of pharyngeal swabs and blood sample as per protocol.
- •5. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other
- •commercial or public health assay in any specimen
- •6.Women of childbearing potential must agree to use at least one primary form of
- •contraception for the duration of the study (acceptable methods will be determined
- •by the site).
排除标准
- •1. Pregnant or breast feeding.
- •2. Allergy to any study medication.
- •3. Severe co-morbidity (e.g. uncontrolled hypertension and uncontrolled DM, systemic disease which affect the vital organs severity, immunocompromised patients etc.) as per investigatorâ??s assessment.
- •4. Comorbid condition like myocardial infarction or heart failure within 90 days of recruitment.
研究者
相似试验
招募中
1 期
A study on the immune response and safety of an RSV vaccine when given to adults 18 years of age and above who received lung or kidney transplant and are at an increased risk of respiratory syncytial virus lower respiratory tract disease and compared to healthy adults 50 years of age and aboveRespiratory Syncytial Virus InfectionsCTIS2023-503951-81-00GlaxoSmithKline Biologicals375
招募中
2 期
A study on the immune response and safety of an RSV vaccine when given to adults 18 years of age and above who received lung or kidney transplant and are at an increased risk of respiratory syncytial virus lower respiratory tract disease and compared to healthy adults 50 years of age and aboveJPRN-jRCT2031230191Ogawa Masayuki375
进行中（未招募）
不适用
A phase II, open-label, controlled, randomized, multicenter study to evaluate the efficacy and safety of pertuzumab Omnitarg , a recombinant humanized antibody against HER2, in combination with carboplatin-based standard chemotherapy versus carboplatin-based standard chemotherapy alone in patients with platinum-sensitive recurrent ovarian cancerEUCTR2005-000557-30-ITROCHE148
进行中（未招募）
不适用
Safety and immunogenicity study of GSK Biologicals’ candidate tuberculosis vaccine (692342) when administered to healthy infants.Healthy volunteers (evaluation of safety and reactogenicity of TB vaccine when administered in healthy infants)EUCTR2012-004380-44-Outside-EU/EEAGlaxoSmithKline Biologicals301
进行中（未招募）
1 期
An interventional study of PDR001 in adult patients with nasopharyngeal carcinoma (NPC) who have progressed on standard treatmentModerately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinomaEUCTR2015-000454-38-FRovartis Pharma Services AG109